Effect of androgens on anemia and malnutrition in renal failure: Implications for patients on peritoneal dialysis

Peritoneal Dialysis International

Volumn 21, Issue 1, 2001, Pages 14-24

  Navarro, J F ^a   Mora, C ^a  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

Author keywords

Androgens; Anemia; Malnutrition; Nandrolone decanoate

Indexed keywords

ANABOLIC AGENT; ANDROGEN; CREATININE; ERYTHROPOIETIN; FLUOXYMESTERONE; HUMAN GROWTH HORMONE; METANDIENONE; METENOLONE ACETATE; METHYLTESTOSTERONE; NANDROLONE DECANOATE; NANDROLONE PHENPROPIONATE; NORETHANDROLONE; OXYMETHOLONE; PLACEBO; RECOMBINANT ERYTHROPOIETIN; STANOZOLOL; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE PROPIONATE;

ACNE; AMENORRHEA; ANEMIA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; ERYTHROPOIESIS; FEMALE; FLUSHING; HEMATOCRIT; HEMATOLOGICAL PARAMETERS; HIRSUTISM; HOARSENESS; HUMAN; HYPERTENSION; KIDNEY DISEASE; LEAN BODY WEIGHT; LIVER ADENOMA; LIVER CELL CARCINOMA; MALE; MUSCLE MASS; NUTRITIONAL PARAMETERS; PELIOSIS HEPATIS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN CALORIE MALNUTRITION; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SPLEEN DISEASE; VIRILIZATION; CHRONIC KIDNEY FAILURE; NUTRITIONAL DISORDER;

ANDROGENS; ANEMIA; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; NUTRITION DISORDERS; PERITONEAL DIALYSIS;

EID: 0035054802     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080102100104     Document Type: Review

References (136)

1. The male sex accessory tissues: Structure, androgen action, and physiology
2. Androgens in men: Uses and abuses
3. Emerging issues in androgen replacement therapy
4. Bioavailability of albumin-bound testosterone
5. Transport of steroid hormones: Binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma
6. Biological actions of androgens
7. To what extent can spermatogenesis be maintained in the hypophysectomized adult rat testis with exogenously administered testosterone?
8. Effects of endogenous testosterone and estradiol on sexual behavior in normal young men
9. Body composition and muscle strength in healthy men receiving testosterone enanthate for contraception
10. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
11. Replacement doses of testosterone increase fat-free mass, muscle size and strength in hypogonadal men
12. Androgens and erythropoiesis
13. Hepatotoxic effects of the anabolic/androgenic steroids
14. Liver pathology associated with the use of anabolic-androgenic steroids
15. Peliosis in renal failure treated with androgens
16. Fulminant hepatic neoplasia after androgen therapy
17. Androgen-associated hepatoma in a hemodialysis patient
18. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels
19. Effects of testosterone supplementation in the aging male
20. Atherogenic effects of anabolic steroids on serum lipid levels. A literature review
21. The effect of testosterone aromatization on high-density lipoprotein cholesterol level and postheparin lipolytic activity
22. Lack of demonstrated effect of nandrolone on serum lipids
23. Nandrolone decanoate reduces lipoprotein(a) concentrations in hemodialysis patients
24. Association of levels of lipoprotein Lp(a), plasma lipids and other lipoproteins with coronary disease documented by angiography
25. Lipoprotein (a). A genetic risk factor for premature coronary heart disease
26. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease
27. Lipoprotein (a) is an independent risk factor for cardiovascular disease in hemodialysis patients
28. Lipids and lipoprotein (a) as risk factors for vascular disease in patients on renal replacement therapy
29. Effects of gonadotropin and testosterone treatment on lipoprotein (a), high density lipoprotein particles, and other lipoprotein levels in male hypogonadism
30. Hormonal regulation of serum lipoprotein (a) levels: Effects of parenteral administration of estrogen or testosterone in males
31. Testosterone decreases lipoprotein(a) in men
32. Effects of nandrolone decanoate (Decadurabolin) on serum Lp(a), lipids and lipoproteins in women with postmenopausal osteoporosis
33. Nandrolone decanoate is a good alternative for the treatment of anemia in elderly male patients on hemodialysis
34. Physiological control of prostatic growth
35. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration
36. Androgens: Risks and benefits
37. Effects of androgen therapy on prostatic markers in hemodialysis patients
38. Erythropoiesis and erythropoietin in patients with chronic renal failure treated with hemodialysis and testosterone
39. Erythropoietic response of dialyzed patients to testosterone
40. Testosterone for anaemia in maintenance dialysis
41. Oxymetholone in the treatment of anaemia in chronic renal failure
42. The hematologic effect of androgen in uremic patients. Study of packed cell volume and erythropoietin responses
43. Nandrolone decanoate therapy for patients receiving hemodialysis: A controlled study
44. Controlled study of androgen therapy in anemia of patients on maintenance hemodialysis
45. Response of uremic patients to nandrolone decanoate
46. The effects of anabolic steroids on growth, body composition, and metabolism in boys with chronic renal failure on regular hemodialysis
47. A comparison of androgens for anemia in patients on hemodialysis
48. Correlation of clinical and in vitro erythropoietic responses to androgens in renal failure
49. Effects of androgenic steroids on erythropoiesis
50. Androgen therapy in haemodialysis patients
51. Prospective controlled study of androgen therapy in the anemia of chronic renal disease: Effects of iron kinetics
52. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease
53. A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis
54. Anabolic steroids in the treatment of malnourished CAPD patients: A retrospective study
55. Evolution of serum erythropoietin after androgen administration to hemodialysis patients: A prospective study
56. Androgen therapy for anaemia of chronic renal failure. Indications in the erythropoietin era
57. Androgen versus erythropoietin for the treatment of anemia in hemodialysis patients: A prospective study
58. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients
59. Androgens for the treatment of anemia in peritoneal dialysis patients
60. Anabolic effects of nandrolone decanoate in patients receiving dialysis
61. Anemia of end-stage renal disease (ESRD)
62. The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin
63. Hormonal factors influencing erythropoiesis
64. Increased erythropoiesis induced by androgenic-hormone therapy
65. The erythrothaemic effects of androgens
66. The effect of sex hormones on the anemia induced by hemorrhage in the rat
67. Effect of castration and sex hormones on blood of the rat
68. Effects of hypophysectomy, castration, and testosterone propionate on hemopoiesis in the adult male rat
69. Cloning and expression of the human erythropoietin gene
70. Correction of anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined Phase I and II clinical trial
71. Correction of anaemia of chronic renal failure with recombinant human erythropoietin: Safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients
72. A multicenter clinical trial of epoetin beta for anemia of end-stage renal disease
73. Mechanism of testosterone action in erythropoiesis
74. Erythropoietin excretion in man following androgens
75. The erythropoietic-stimulating effects of androgens
76. The effect of testosterone on erythropoietin levels in anemic patients
77. Erythropoietin and erythropoiesis in anemic man following androgens
78. Inhibition of erythropoiesic effects of hormones by erythropoietin antisera in mildly plethoric mice
79. Mechanisms of action of androgen treatment on the anemia of experimental chronic renal failure
80. Effects of testosterone and erythropoietin erythroid colony formation in human bone marrow cultures
81. Steroids and hematopoiesis I. The effect of steroids on in vitro erythroid colony growth: Structure/activity relationships
82. The role of androgens in the treatment of anemia of chronic renal failure
83. Effect of steroids on the cycling of haematopoietic stem cells
84. Effects of androgen on transient endogenous spleen colonies and other hemopoietic stem cells in mice
85. Stimulatory effects of androgens on normal children's bone marrow in culture: Effects on BFU-E, CFU-E, and uroporphyrinogen I synthase activity
86. Enhanced erythroid burst formation in mice after testosterone treatment
87. Stimulation of hemoglobin synthesis in chick blastoderms by certain 5 β androstane and 5 β pregnane steroids
88. Studies on the control of hemoglobin synthesis: The in vitro stimulating effect of a 5β-H steroid metabolite on heme formation in human bone marrow cells
89. Steroid control of porphyrin and heme biosynthesis: A new biological function on steroid hormone metabolites
90. Enhancement of heme and globin synthesis in cultured human marrow by certain 5 beta H steroid metabolites
91. Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin
92. Erythropoietin and hypertension
93. Improvement of erythropoietin-induced hypertension changing the administration route
94. Cost implications to Medicare of recombinant erythropoietin therapy for the anemia of end-stage renal disease
95. Survey of the management of anemia in endstage renal disease (ESRD)
96. Nutritional status of patients undergoing continuous ambulatory peritoneal dialysis (CAPD)
97. Nutrition and delayed hypersensitivity during continuous ambulatory peritoneal dialysis in relation to peritonitis
98. Whole body leucine turnover and nutritional status in continuous ambulatory peritoneal dialysis
99. Nutritional status of patients on hemodialysis and peritoneal dialysis
100. Plasma and muscle free amino acids during continuous ambulatory peritoneal dialysis
101. Nutritional assessment of continuous ambulatory peritoneal dialysis patients: An international study
102. Nutritional status in long-term CAPD patients
103. The normalized protein catabolic rate is a flawed marker of nutrition in CAPD patients
104. Cross-sectional comparison of malnutrition in continuous ambulatory peritoneal dialysis and hemodialysis patients
105. Anthropometric norms for the dialysis population
106. Malnutrition as the main factor in morbidity and mortality of hemodialysis patients
107. Nutritional assessment of continuous ambulatory peritoneal dialysis patients
108. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities
109. Effect of nutrition on morbidity and mortality in maintenance dialysis patients
110. Adequacy of dialysis and nutrition in continuous ambulatory peritoneal dialysis: Association with clinical outcomes
111. Serum albumin: A marker of morbidity in peritoneal dialysis patients
112. Predictors of survival in continuous ambulatory peritoneal dialysis patients: The importance of prealbumin and other nutritional and metabolic markers
113. Death risk predictors among peritoneal dialysis and hemodialysis patients: A preliminary comparison
114. Predictors of survival in continuous ambulatory peritoneal dialysis patients: A five-year prospective study
115. Serum albumin in continuous peritoneal dialysis: Its predictors and relationship to urea clearance
116. How much peritoneal dialysis is required for the maintenance of a good nutritional state?
117. Dialysis adequacy and nutrition determine prognosis in continuous ambulatory peritoneal dialysis patients
118. Influence of initial nutritional status on continuous ambulatory peritoneal dialysis patient survival
119. Preventing malnutrition in the long-term peritoneal dialysis patients
120. Interventions to treat malnutrition in dialysis patients: The role of the dose of dialysis, intradialytic parenteral nutrition, and growth hormone
121. Nutritional management of the continuous ambulatory peritoneal dialysis patient
122. Therapeutic approaches to malnutrition in chronic dialysis patients: The different modalities of nutritional support
123. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis
124. Testosterone injection stimulates net muscle protein synthesis but not amino acid transport
125. Androgens
126. Protein energy malnutrition in severe alcoholic hepatitis: Diagnosis and response to treatment
127. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease: A placebo-controlled randomized trial
128. The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients
129. Oxandrolone, an anabolic steroid, significantly increases the rate of weight gain in the recovery phase after major burns
130. Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection
131. Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial
132. Treatments for wasting in patients with the acquired immunodeficiency syndrome
133. The use and misuse of androgens
134. Effects of anabolic steroid (AS) on nutritional parameters in malnourished CAPD patients
135. Clinical practice guidelines for the treatment of anemia of chronic renal failure